|

SHR-A1811 Injection Clinical Trials

4 actively recruiting trials

Pipeline

Phase 2: 3Phase 3: 1

Top Sponsors

  • Jiangsu HengRui Medicine Co., Ltd.3
  • Shengjing Hospital1

Indications

  • Cancer4
  • Breast Cancer2
  • HER2-PositiveRecurrent or Metastatic Breast Cancer1
  • Recurrent or Metastatic Cervical Cancer1
  • HR Positive/HER2 Low Breast Cancer1

Other4 trials

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Phase 2
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Phase 3
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
Phase 2
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.